Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Cash Flows (Unaudited)

v3.22.2.2
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Loss for the period $ (4,596) $ (5,966)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation of property and equipment 15 15
Change in fair value of milestone liability (87) (3)
Warrants issued for services   31
Stock option expense 518 811
Changes in operating assets and liabilities    
Prepaid expenses, deposits and other (40) (13)
Clinical trial deposit (1,700)  
Accounts payable and accrued liabilities (331) 122
Related party payables (148) (70)
Net cash used in operating activities (6,369) (5,073)
Cash flows from investing activities    
Purchase of equipment (232)  
Net cash used in investing activities (232)  
Cash flows from financing activities    
Net proceeds from the issuance of shares and warrants 1,908 13,803
Warrants exercised for cash   74
Series A preferred cash dividend (2) (2)
Net cash provided by financing activities 1,906 13,875
(Decrease) increase in cash and cash equivalents (4,695) 8,802
Cash and cash equivalents – beginning of period 11,780 10,537
Cash and cash equivalents – end of period $ 7,085 $ 19,339